[Gyrase inhibitors: unwanted central nervous system effects].
Rietbrock
N
N
Staib
A H
AH
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001923:Brain Chemistry; D001927:Brain Diseases / Q000139:chemically induced*; D002939:Ciprofloxacin / Q000009:adverse effects; D015365:Enoxacin; D006801:Humans; D009287:Naphthyridines / Q000009:adverse effects; D009643:Norfloxacin / Q000009:adverse effects / Q000031:analogs & derivatives; D015242:Ofloxacin; D010078:Oxazines / Q000009:adverse effects; D015366:Pefloxacin; D012995:Solubility
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D009287:Naphthyridines; D010078:Oxazines; D015366:Pefloxacin; D015365:Enoxacin; D002939:Ciprofloxacin; D015242:Ofloxacin; D009643:Norfloxacin
Gyrase-Hemmer: unerwünschte zentralnervöse Wirkungen.